OY-TES-1在肝细胞癌中的表达及抗体血清学分析

OY-TES-1 expression and serum immunoreactivity in hepatocellular carcinoma

目的:了解OY-TES-1在肝细胞癌(HCC)中的表达及其抗体出现情况,探讨将OY-TES-1用于肿瘤免疫诊疗的可能性.方法:利用实时定量PCR和免疫组织化学技术,从 mRNA和蛋白质两个水平研究OY-TES-1在HCC中的表达特点;采用酶联免疫吸附实验检测HCC患者及正常人血清中相应的抗体,并对其临床意义做初步的分析.结果:经实时定量PCR检测,HCC中OY-TES-1 mRNA阳性率为73.21%(41/56),癌旁阳性率为64.86%(24/37),有17对HCC及配对癌旁组织均表达阳性,OY-TES-1 mRNA在HCC及癌旁组织两者的表达阳性率无差异(P>0.05);在37对HCC及配对癌旁组织中,HCC中OY-TES-1 mRNA水平明显高于对应的癌旁组织,其差异与病理分级有关(P<0.05).HCC中OY-TES-1蛋白阳性率为40%(4/10).血清学检测未发现76例正常人和17例肝硬化患者血清中有相应抗体,HCC患者血清抗体阳性率为20%(12/58),OY-TES-1血清抗体的出现与HCC患者的年龄、性别等临床资料无相关.结论:OY-TES-1在HCC中有较高的表达频率及表达水平,该蛋白具有较强的免疫原性,他有望作为用于HCC辅助诊断及免疫治疗的肿瘤抗原.

AIM： To investigate OY-TES-1 expression and serum immunoreactivity in human hepatocellular carcinoma （HCC） and explore the possibility of using OY-TES-1 as a target for immunotherapy and auxiliary diagnosis of HCC. METHODS： The expression of OY-TES-1 mRNA and protein was detected by real-time PCR and immunohistochemistry, respectively. The presence of serum OY-TES-1 antibody in normal individuals and patients with HCC or hepatocirrhosis was determined by enzyme-linked immunosorbent assay （ELISA） using purifi ed OYTES-1 as the antigen. The clinical signif icance of OY-TES-1 expression and serum immunoreactivity in HCC was then analyzed. RESULTS： The positive rates of OY-TES-1 mRNA expression in HCC and tumor-adjacent tissue were 73.21% （41/56） and 64.86% （24/37）, respectively, showing no signif icant difference （P 〉 0.05）. The expression level of OY-TES-1 mRNA in HCC tissue was signifi cantly higher than that in tumor-adjacent tissue （P 〈 0.05）. The expression level of OY-TES-1 mRNA was correlated with histological grade of HCC. The positive rate of OY-TES-1 protein expression in HCC tissue was 40% （4/10）. The positive rate of serum OY-TES-1 antibody was 20% in HCC patients, while no serum reactivity to OY-TES-1 was detected in 76 normal individuals and 17 patients with hepatocirrhosis. No correlation was found between the presence of OY-TES-1 antibody and clinical and pathological parameters in HCC.CONCLUSION： OY-TES-1 shows high-level expression and high serum immunoreactivity in HCC and is therefore a potential target for antigen-specific immunotherapy and auxiliary diagnosis of HCC.